A Phase 3 interventional study of Doxorubicin and Cyclophosphamide in Breast Neoplasms, sponsored by Sanofi. Completed at 42 sites in 42 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-11-15.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 197 studies testing doxorubicin in Breast Neoplasms — 9 open to participants now, 18 under way, 5 of them phase 3. Doxorubicin · Breast Neoplasms.
Among the 197 studies testing doxorubicin in Breast Neoplasms, this one is the 8th largest by enrollment of the 189 interventional ones that give a count, is one of 7 that started in 2001, is one of 28 in phase 3, and was the 28th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →9 of the 197 studies testing doxorubicin in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–70
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70 · Women only
SCRI Development Innovations, LLC · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
197 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 126 · Phase 3 30 · Phase 4 9
First in 1993; this study’s year is marked. 7 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,222 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 56 across the 189 interventional studies. Of the 142 that completed or were terminated, 69 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 197 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
40 studies in Breast Neoplasms by Sanofi: none open now, none under way, none of them phase 3. Of 39 finished, 14 (36%) have results posted.
Among the 40 studies in Breast Neoplasms by Sanofi, this one is the 2nd largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2001, is one of 11 in phase 3, and was the 2nd registered.
Sanofi’s Breast Neoplasms studies by the year they started, since 1994.
4 of the studies testing doxorubicin in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05645380University of Kansas Medical CenterNeoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | 2026-12 |
| NCT02897700Shanghai Jiao Tong University School of MedicineA Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast | 2026-12 |
| NCT03971409Laura Huppert, MD, BAAvelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | 2027-01-31 |
| NCT05748834SCRI Development Innovations, LLCStudy of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 197 studies testing doxorubicin in Breast Neoplasms, from their registry updates:
Among Sanofi’s 40 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective:
Secondary objective:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Laboratory requirements: (within 14 days prior to registration)
a) Hematology: i) Neutrophils ≥ 2.0 109/L ii) ≥ 100 109/L iii) ≥ 10 g/Dl
b) Hepatic function: i) Total ≤ 1 UNL ii) (ASAT) (Serum glutamic oxaloacetic transaminase [SGOT]) and alanine amino transferase (ALAT) (Serum glutamic-pyruvic transaminase [SGPT]) ≤ 2.5 UNL iii) Alkaline phosphatase ≤ 5 UNL iv) Participants with ASAT and/or ALAT > 1.5 x UNL associated with alkaline phosphatase > 2.5 x UNL are not eligible for the study.
c) Renal function: i) Creatinine ≤ 175 µmol/L (2 mg/dL) ii) If creatinine was 140 - 175 μmol/L, the calculated should be ≥ 60 mL/min.
Exclusion criteria:
Cardiac disease that would preclude the use of doxorubicin, docetaxel and Herceptin:
Other serious illness or medical condition:
Past or current history of neoplasm other than breast carcinoma, except for:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Doxorubicin 60 mg/m² intravenous (IV) bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus injection on Day 1 of every 3 weeks for 4 cycles followed by docetaxel 100 mg/m² IV infusion every 3 weeks for another 4 cycles.
Drug: Doxorubicin · Drug: Cyclophosphamide · Drug: Docetaxel
Doxorubicin 60 mg/m² IV bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus Injection on Day 1 of every 3 weeks for 4 cycles. Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV infusion on Day 2 of Cycle 5, then on Day 1 of every 3 weeks for all subsequent cycles ( total 4 cycles). After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
Drug: Doxorubicin · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Herceptin
Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 1 only, followed by Herceptin 2 mg/kg IV infusion weekly starting from Day 8 until three weeks after the last cycle of chemotherapy. Docetaxel 75 mg/ m² IV infusion on Day 2 of Cycle 1, then on Day 1 of all subsequent cycles followed by carboplatin IV infusion at target AUC = 6 mg/mL/min repeated every 3 weeks for a total of 6 cycles. After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg by IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
Drug: Docetaxel · Drug: Herceptin · Drug: Carboplatin
Also known as: Taxotere
Also known as: Trastuzumab
Percentage of Participants With Disease Free Survival at 5 Years
Disease Free Survival was defined as the interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix) or death from any cause whichever occured first. Disease free survival was estimated using the Kaplan-Meier method.
Time frame: From randomization until relapse or death or up to 5 years
Percentage of Participants With Disease Free Survival at 10 Years
Disease free survival was defined as the interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix) or death from any cause whichever occured first. Disease free survival was estimated using the Kaplan-Meier method.
Time frame: From randomization until relapse or death or up to 10 years
Overall Survival- Percentage of Participants Who Survived at 10 Years
Overall survival of the participants was measured from the date of randomization up to the date of death due to any cause. Overall survival was estimated using the Kaplan-Meier method.
Time frame: From randomization until death or up to 10 years
The study was conducted at 433 centers in 43 countries. A total of 3222 participants randomized between 05 April 2001 and 30 March 2004. Participants stratified according to institution, nodal status(negative, positive 1-3 nodes, positive 4 or more nodes) and hormonal receptor status (estrogen and/or progesterone receptor positive versus negative).
| Milestone | Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T) | AC Followed by Docetaxel + Herceptin (AC→TH) | Docetaxel + Carboplatin + Herceptin (TCH) |
|---|---|---|---|
| Started | 1073 | 1074 | 1075 |
| Treated | 1045 | 1072 | 1057 |
| Safety population | 1018 | 1100 | 1056 |
| Completed | 952 | 804 | 926 |
| Not completed | 121 | 270 | 149 |
| Withdrew: Death | 1 | 0 | 2 |
| Withdrew: Breast cancer relapse | 5 | 18 | 11 |
| Withdrew: Second primary malignancy | 0 | 4 | 1 |
| Withdrew: Withdrawal by subject | 41 | 64 | 26 |
| Withdrew: Lost to follow-up | 0 | 2 | 3 |
| Withdrew: Cardiac toxicity | 0 | 61 | 32 |
| Withdrew: Herceptin toxicity | 0 | 22 | 6 |
| Withdrew: Adverse event | 46 | 30 | 18 |
| Withdrew: Protocol violation | 0 | 2 | 0 |
| Withdrew: Other than specified above | 0 | 38 | 19 |
| Withdrew: Missing | 0 | 27 | 13 |
| Withdrew: Randomized but not treated | 28 | 2 | 18 |
Disease Free Survival was defined as the interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix) or death from any cause whichever occured first. Disease free survival was estimated using the Kaplan-Meier method.
| percentage of participants | Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T) | AC Followed by Docetaxel + Herceptin (AC→TH) | Docetaxel + Carboplatin + Herceptin (TCH) |
|---|---|---|---|
| Percentage of Participants With Disease Free Survival at 5 Years | 75.5 (72.8 to 78.2) | 83.2 (80.9 to 85.4) | 81.0 (78.6 to 83.4) |
Disease free survival was defined as the interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix) or death from any cause whichever occured first. Disease free survival was estimated using the Kaplan-Meier method.
| percentage of participants | Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T) | AC Followed by Docetaxel + Herceptin (AC→TH) | Docetaxel + Carboplatin + Herceptin (TCH) |
|---|---|---|---|
| Percentage of Participants With Disease Free Survival at 10 Years | 67.2 (64.2 to 70.2) | 73.4 (70.6 to 76.2) | 72.3 (69.4 to 75.1) |
Overall survival of the participants was measured from the date of randomization up to the date of death due to any cause. Overall survival was estimated using the Kaplan-Meier method.
| percentage of particpants | Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T) | AC Followed by Docetaxel + Herceptin (AC→TH) | Docetaxel + Carboplatin + Herceptin (TCH) |
|---|---|---|---|
| Overall Survival- Percentage of Participants Who Survived at 10 Years | 78.9 (76.2 to 81.5) | 86.0 (83.8 to 88.2) | 83.4 (81.0 to 85.8) |
Collected over All Adverse Events (AE) were collected from the time the participant started treatment with study drug until 30 days after the last infusion of study treatment (chemotherapy or Herceptin).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T) | — | 218/1,018 (21.4%) | 1,017/1,018 (99.9%) |
| AC Followed by Docetaxel + Herceptin (AC→TH) | — | 298/1,100 (27.1%) | 1,100/1,100 (100%) |
| Docetaxel + Carboplatin + Herceptin (TCH) | — | 283/1,056 (26.8%) | 1,052/1,056 (99.6%) |
| Event | Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T) | AC Followed by Docetaxel + Herceptin (AC→TH) | Docetaxel + Carboplatin + Herceptin (TCH) |
|---|---|---|---|
| FEVERGeneral disorders | 85/1018 | 109/1100 | 86/1056 |
| INFECTIONGeneral disorders | 68/1018 | 85/1100 | 85/1056 |
| LEFT HEART FAILURECardiac disorders | 8/1018 | 25/1100 | 2/1056 |
| LEUKOPENIABlood and lymphatic system disorders | 21/1018 | 23/1100 | 20/1056 |
| VOMITINGGastrointestinal disorders | 12/1018 | 16/1100 | 11/1056 |
| DEEP THROMBOPHLEBITISCardiac disorders | 6/1018 | 13/1100 | 15/1056 |
| DIARRHEAGastrointestinal disorders | 2/1018 | 10/1100 | 11/1056 |
| CELLULITISGeneral disorders | 7/1018 | 7/1100 | 11/1056 |
| ANEMIABlood and lymphatic system disorders | 1/1018 | 8/1100 | 9/1056 |
| STOMATITISGastrointestinal disorders | 7/1018 | 4/1100 | 1/1056 |
| Event | Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T) | AC Followed by Docetaxel + Herceptin (AC→TH) | Docetaxel + Carboplatin + Herceptin (TCH) |
|---|---|---|---|
| ALOPECIASkin and subcutaneous tissue disorders | 1003/1018 | 1083/1100 | 1018/1056 |
| NAUSEAGastrointestinal disorders | 890/1018 | 967/1100 | 863/1056 |
| ASTHENIAGeneral disorders | 838/1018 | 925/1100 | 878/1056 |
| STOMATITISGastrointestinal disorders | 660/1018 | 735/1100 | 564/1056 |
| DIARRHEAGastrointestinal disorders | 439/1018 | 555/1100 | 658/1056 |
| VOMITINGGastrointestinal disorders | 563/1018 | 628/1100 | 428/1056 |
| MYALGIAMusculoskeletal and connective tissue disorders | 541/1018 | 614/1100 | 415/1056 |
| NEUROPATHYNervous system disorders | 514/1018 | 569/1100 | 406/1056 |
| NAIL DISORDERSkin and subcutaneous tissue disorders | 507/1018 | 484/1100 | 303/1056 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 439/1018 | 515/1100 | 335/1056 |
Intent-To-Treat (ITT) population included all randomized participants.
| Age, Continuous(years) | Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T) | AC Followed by Docetaxel + Herceptin (AC→TH) | Docetaxel + Carboplatin + Herceptin (TCH) | Total |
|---|---|---|---|---|
| Mean | 48.8 ± 9.7 | 48.7 ± 9.7 | 48.6 ± 9.9 | 48.7 ± 9.8 |
| Sex: Female, Male(Participants) | Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T) | AC Followed by Docetaxel + Herceptin (AC→TH) | Docetaxel + Carboplatin + Herceptin (TCH) | Total |
|---|---|---|---|---|
| Female | 1073 | 1074 | 1075 | 3222 |
| Male | 0 | 0 | 0 | 0 |
The record gives a start of Apr 2001, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Doxorubicin · Cyclophosphamide · Trastuzumab · Carboplatin